Six African countries have been chosen to build vaccine production factories as part of a bid the World Health Organization launched last year to replicate what are believed to be the most effective licensed shots against Covid-19.
According to WHO figures, only 11% of the population in Africa is fully vaccinated, compared with the global average of about 50%.
The first African countries selected to receive the technology necessary to produce mRNA vaccines against Covid-19 are Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia.
WHO Secretary-General Tedros Adhanom Ghebreyesus told the Brussels Summit meeting that, although in excess of 10 billion dosess of Covid-19 antibodies have been administered all around the world, billions of individuals actually stay unvaccinated.
As per Tedros, billions of people are yet to profit from these life-saving apparatuses, hence, has called for a pressing increase of local production of shots in poor countries.
It is the first time WHO has supported efforts to reverse-engineer a commercially-sold vaccine, making an end run around the pharmaceutical industry that has largely prioritized supplying rich countries over poor in both sales and manufacturing.
The U.N.-backed effort known as COVAX to distribute Covid-19 vaccines fairly to lower-income countries has missed numerous targets and only about 10% of people in poorer countries have received at least one dose.
Recently, the Cape Town organization endeavoring to repeat Moderna’s Covid-19 shot said it had successfully made an candidate immunization that will soon beginning research center testing.
Both Moderna and Pfizer-BioNTech, producers of the two approved mRNA Covid-19 antibodies, have declined to share their vaccination formula or technology expertise with WHO and its partners.
In any case, according to experts, the fastest way to start vaccine production in African countries and other regions with limited vaccine production is still through full and transparent transfer of vaccine know-how of already-approved mRNA technologies to able companies.
Thusly, research shows that there are in excess of 100 manufacturers in Asia, Africa and Latin America that could make the antibodies.
Recently, BioNTech said that it would begin sending transporting holder measured processing plants to African nations to assist them with beginning producing their Covid-19 antibody with European staff, in what a few activists called a “neo-colonial stunt” to keep up with control.
In spite of the fact that Moderna promised not to follow organizations for encroaching on its Covid antibody licenses, it as of late documented cases for quite a long time licenses in South Africa.
The move raised apprehensions the organization will start implementing licenses while Covid-19 is as yet spreading in Africa, sabotaging efforts to build African vaccination production.
In addition to supporting the transfer of vaccine technology, the EU has been exporting millions of Covid-19 vaccine doses to Africa. The 27-nation bloc said it has supplied Africa with almost 145 million doses, with a goal of reaching at least 450 million shots by summer.